Compare Inovio Pharmaceuticals Inc (INO) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Materials Select Sector SPDR Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Materials Select Sector SPDR Fund trades at $50.28. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | XLB | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | — |
52-Week High | $2.87 | $53.62 |
52-Week Low | $1.05 | $42.23 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
XLB trades at $50.03, down 0.99% with a bearish technical bias as moving averages signal selling pressure. The materials ETF faces mixed sentiment with neutral oscillators and key support at $50. Recent news highlights sector rotation potential amid Q2 earnings growth, though Seeking Alpha rates it Hold citing limited upside after recent gains.
Outlook remains cautious with geopolitical and inflation risks weighing on materials demand. Infrastructure trends offer long-term support, but current valuations may already reflect cyclical recovery. Investors should monitor earnings momentum and sector rotation flows for entry opportunities amid bearish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
